 BOSTON, Dec. 08, 2022 GLOBE NEWSWIRE Replimune Group, Inc. Nasdaq: REPL, a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of 23.50 per share. In addition, in lieu ... The post Replimune Announces Pricing of Public Offering appeared first on ForexTV... 